AlloFlo™ Uveo / AlloSert™ Uveo System

About Iantrek

Iantrek is a private, clinical-stage medical device company developing innovative solutions for interventional glaucoma surgery. The company's core technology platform targets the uveoscleral outflow pathway, with its lead product, AlloFlo™ Uveo, already used in over 3,000 U.S. cases and supported by robust clinical data from the CREST study. Founded in 2018 and based in San Diego, Iantrek recently secured a $42 million Series C financing to support the commercial launch of its breakthrough therapy.

Therapeutic Areas